A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
Primary Purpose
Hypoplasminogenemia
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Plasminogen (Human)
Sponsored by

About this trial
This is an expanded access trial for Hypoplasminogenemia
Eligibility Criteria
Inclusion Criteria:
- Patient has provided informed consent.
- Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.
Exclusion Criteria:
- Not applicable
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT03265171
First Posted
August 25, 2017
Last Updated
April 22, 2020
Sponsor
Prometic Biotherapeutics, Inc.
Collaborators
Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03265171
Brief Title
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
Official Title
A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Prometic Biotherapeutics, Inc.
Collaborators
Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.
4. Oversight
5. Study Description
Brief Summary
These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoplasminogenemia
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
Plasminogen (Human)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Months
Eligibility Criteria
Inclusion Criteria:
Patient has provided informed consent.
Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.
Exclusion Criteria:
Not applicable
12. IPD Sharing Statement
Learn more about this trial
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
We'll reach out to this number within 24 hrs